Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry.

CONCLUSIONS: iRUF approximated post-implant CT/MRI prostate and urethral dosimetry to a greater degree than USD. A phase II trial utilizing iRUF for intraoperative dynamic plan modification is underway, with the goal to confirm capability to minimize and correct for prostate underdosage not otherwise detected. PMID: 28647400 [PubMed - as supplied by publisher]
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research

Related Links:

PROSTATE cancer is the most common cancer in men in the UK. Spotting the warning signs significantly improves a person ’s outcome. If the cancer has spread, symptoms can show up in different parts of the body. One sign of advanced cancer can have a profound impact on a person’s day to day life.
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Males who carry BRCA1 or BRCA2 mutations are at increased risk of prostate cancer (PC), a new prospective study confirms.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Clinical guidelines recommending hormone therapy with radiotherapy in prostate cancer may need to be revisited.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Emodin: Its role in prostate cancer‑associated inflammation (Review). Oncol Rep. 2019 Aug 06;: Authors: Tu Y, Wu Z, Tan B, Yang A, Fang Z Abstract Prostate cancer is one of the most common malignancies diagnosed in males. Cancer‑related inflammatory factors include tumor necrosis factor, inflammasomes, cytokines, chemokines, transcription factors, infiltrating or circulating immune cells, reactive oxygen species, and sex hormone receptors. These are mainly associated with the local immune response at the tumor site. Emodin, a chemical compound that can be isolated from the plant rhubarb among other...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
High-dose, precision radiation therapy extends progression-free survival in recurrent prostate cancer with limited metastatic spread and prevents the development of new lesions at 6 months.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
CHICAGO - The use of stereotactic ablative radiotherapy (SABR) to treat men...Read more on AuntMinnie.comRelated Reading: ASTRO: Is hormone therapy after prostate surgery needed? Ga-68 PSMA PET/MRI, mpMRI work for prostate cancer analysis AI, radiomics predict prostate cancer aggressiveness NaF-PET/CT does well in detecting prostate metastases ASTRO: SABR is effective for oligometastatic cancers
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
TUESDAY, Sept. 17, 2019 -- In what might be a major breakthrough, researchers report that high doses of radiation dramatically prolonged survival in men battling an advanced and aggressive form of prostate cancer. This particular type of cancer...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
In this study we aimed to test the clinical implications of capsular abutment or bulging on preoperative multiparametric magnetic resonance imaging (mpMRI). METHODS: We analyzed the data of 291 patients who underwent radical prostatectomy (RP) for a cT1-2N0 prostate cancer in a single surgeon series. All patients underwent preoperative staging with mpMRI. PIRADS v2 was used for characterizing lesions. The role of capsular abutment or bulging was tested in a multivariable logistic regression adjusting for PSA and highest ipsilateral biopsy Gleason grade. The presence of focal vs. extensive ECE was investigated. RESU...
Source: Minerva Urologica e Nefrologica - Category: Urology & Nephrology Tags: Minerva Urol Nefrol Source Type: research
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with diverse drivers of disease progression and mechanisms of therapeutic resistance. We conducted deep phenotypic characterization of CRPC metastases and patient-derived xenograft (PDX) lines using whole-genome RNA sequencing, gene set enrichment analysis, and immunohistochemistry. Our analyses revealed 5 mCRPC phenotypes based on the expression of well-characterized androgen receptor (AR) or neuroendocrine (NE) genes: AR-high tumors (ARPC), AR-low tumors (ARLPC), amphicrine tumors composed of cells coexpressing AR and NE genes (AMPC), doub...
Source: Journal of Clinical Investigation - Category: Biomedical Science Authors: Source Type: research
This study identifies novel mechanistic targets of WA in prostate cancer.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | PET Scan | Prostate Cancer | Radiology | Study | Ultrasound